Zedira GmbH
Darmstadt
About Zedira GmbH
Zedira GmbH is a clinical stage biotech company that specializes in transglutaminase. The company develops small molecular drug candidates and engages in the discovery of small molecules that block dysregulated transglutaminases. It is a global brand for specialty reagents for research and development as well as diagnostics in the transglutaminase field. They offer TG6, a neuronal transglutaminase marker used in detecting neurological disorders caused by gluten. The company also produces and markets specialty reagents to assist investigators who are studying celiac disease; and develops active ingredients and celiac disease diagnostic antigens. ZEDIRA GmbH also provides proteases, assays, substrates, antibodies, inhibitors, and autoantibody detection ELISA-Kits. Zedira was founded by Ralf Pasternack and Martin Hils in 2007; and is headquartered in Hessen, Germany.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.6M
- Funding stage: Seed
- Last round: Grant (Nov 2016)
- Website: zedira.com
- Phone: 49 6151 3251-00
Industries & Categories
Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/zedira-gmbh-134685 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.